EP Patent

EP2589594A1 — Ivabradine hydrochloride Form IV

Assigned to Urquima SA · Expires 2013-05-08 · 13y expired

What this patent protects

Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation,and its use as therapeutically active ingredient.

USPTO Abstract

Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation,and its use as therapeutically active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2589594A1
Jurisdiction
EP
Classification
—
Expires
2013-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Urquima SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.